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MicroRNAs (miRNAs) are a class of non-coding small RNAs with critical regulatory func-
tions as post-transcriptional regulators. Due to the fundamental importance and broad
impact of miRNAs on multiple genes and pathways, dysregulated miRNAs have been
associated with human diseases, including cancer. Colorectal cancer (CRC) is among the
most deadly diseases, and miRNAs offer a new frontier for target discovery and novel
biomarkers for both diagnosis and prognosis. In this review, we summarize the recent
advancement of miRNA research in CRC, in particular, the roles of miRNAs in CRC stem
cells, epithelial-to-mesenchymal transition, chemoresistance, therapeutics, diagnosis, and
prognosis.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancer types
and causes 655,000 deaths per year worldwide (Alwan, 2007). In
the United States, CRC ranks second in cancer-related mortality
(Hegde et al., 2008). It is estimated that over 141,000 new CRC
cases will be diagnosed and more than 49,000 CRC patients will
die in the year of 2011 according to the National Cancer Insti-
tute. Many early detection methods and therapeutic approaches
have been explored to further improve the CRC treatment and
prolong patient survival in the last 20 years (Hegde et al., 2008).
CRC is a heterogeneous tumor containing different cell popu-
lations with distinct properties, which contribute to the disease
complexity and lead to variable clinical patterns, including symp-
toms, tumor development, responses to treatments, and patients
outcomes (Gutman and Fidler, 1995). Therefore, there is an urgent
need to discover and develop reliable, highly sensitive, and speciﬁc
novel comprehensive diagnostic biomarkers, which can predict
the prognosis and provide the basis for individualized therapeutic
strategies against CRC.
Recently, small regulatory RNAs have gained tremendous inter-
est in cancer research.MicroRNAs (miRNAs) are non-codingRNA
molecules, 18–25 nucleotide in length, that regulate the expression
of their target genes by translational arrest ormRNAcleavage,most
likely, through interaction mainly at the 3′-UTRs of the target
mRNAs (Lee et al., 1993; Wightman et al., 1993; He and Hannon,
2004). Base pairing between at least six consecutive nucleotides
within the 5′-seed of the miRNAwith the target site on the mRNA
is reported to be a minimum requirement for the miRNA–mRNA
interaction (Lee et al., 1993; Wightman et al., 1993). miRNAs
have been found to regulate many cellular processes including
apoptosis (Brennecke et al., 2003; Chan et al., 2005; Hwang and
Mendell, 2006; Ghodgaonkar et al., 2009), differentiation (Wight-
man et al., 1993; Navarro and Lieberman, 2010; Tang, 2010), and
cell proliferation (Brennecke et al., 2003; He et al., 2005; John-
son et al., 2007; Navarro and Lieberman, 2010). Dysregulation
of miRNAs have been associated with cancer development and
progression, and miRNAs emerge as a new research frontier for
understanding cancer development at the post-transcriptional and
translational level (Ryan et al., 2010).
GENOMICS PROFILING TO DISCOVER miRNAs ASSOCIATED
WITH COLORECTAL CANCER
The discovery of miRNAs associated with CRC began with
high throughput systematic miRNA expression proﬁling. The
ﬁrst report of dysregulated miRNAs in CRC was published in
2003 (Michael et al., 2003), of which they discovered the down-
regulation of miR-143 and miR-145 in CRC tumor tissues com-
pared to the normal controls. Subsequently, several additional
studies have been conducted to proﬁle the expression levels of
miRNAs in both CRC cell lines and tumor specimens, which pro-
vided more than 100 dysregulated miRNAs. Among these, several
miRNAs were found to be consistently deregulated in CRC spec-
imens, such as overexpression of miR-20, miR-21, miR-31, and
miR-99b, and the reduction of miR-143, miR-145, and miR-192
(Bandres et al., 2006;Volinia et al., 2006; Slaby et al., 2007; Schetter
et al., 2008; Chen et al., 2009).With regards to disease progression,
miRNA levels were found to be associated with CRCdisease stages,
for example, the expression of miR-31 was signiﬁcantly higher in
stage IV tumors than that in stage II tumors, andmiR-21was found
to be positively related to CRCmetastasis and clinical stages (Slaby
et al., 2007). Slattery et al. quantiﬁed the miRNA expression levels
based on tumor location and mutation status of p53 and KRAS.
There were 73 differentially expressed miRNAs between normal
tissues from colon and rectum with at least twofold difference.
The tumors were further categorized into several subtypes based
on microsatellite instability, CpG Island Methylator Phenotype,
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KRAS2-mutation, and p53 mutation. Each subtype had a unique
miRNA proﬁle, indicating a potential of different genetic factors
to inﬂuence miRNA expression levels (Slattery et al., 2011). More
recently, a comprehensive genome wide analysis for the contri-
bution of epigenetic mechanisms to miRNA dysregulation was
conducted in CRC by high-resolution chromatin immunopre-
cipitation (ChIP)-sequencing approach. They have identiﬁed 47
miRNAs encoded in 37 primary transcription units as potential
targets of epigenetic silencing. Among the miRNAs we found to
be dysregulated, many of which are implicated in human cancer,
miR-1-1 was methylated frequently in early and advanced CRC in
which it may act as a tumor suppressor. These ﬁndings provide
a new insight into the association between chromatin signatures
and miRNA dysregulation in cancer (Suzuki et al., 2011). Given
these ﬁndings, some of these miRNAs may be potential candi-
dates as novel therapeutic targets and/or diagnostic and prognostic
biomarkers.
Although currently there is still no experimental evidence that
any dysregulated miRNAs directly cause the pathogenesis of CRC
development, mounting evidence indicates that there is a close
connection between inﬂammation and tumorigenesis (Williams
et al., 1999; Hanada et al., 2006; Feagins et al., 2009; Dupaul-
Chicoine et al., 2010). The pathogenesis of CRC is a rather compli-
cated process and inﬂammation directly contributes to the devel-
opment of CRC. In the case of CRC, the inﬂuence of miRNAs in
inﬂammation and tumorigenesis was also investigated. It has been
shown that expression levels of miRNAs are inﬂuenced by inﬂam-
mation (Sonkoly et al., 2008). Necela et al. compared the miRNA
expression levels in mouse CRC samples derived from chronic
inﬂammation and genetic mutation. miR-215, miR-708, miR-31,
and miR-135b were found consistently deregulated in both stud-
ies. miR-137, miR-133a, miR-467d, and miR-218 were uniquely
differentially expressed in the mouse model (Necela et al., 2011).
p53 AND miRNAs
It is well established that p53, a tumor suppressor gene, is among
the most frequently deleted and mutated genes in many cancers,
and the frequency inCRC is over 50%(Crawford et al.,1984;Vogel-
stein et al., 1988; Scott et al., 1991). p53 regulates its target gene
expression at several levels. It functions either as a transcriptional
activator or suppressor in certain cases in response to genotoxic
and growth stresses respectively (Zhao et al., 2000). It can also
act as an RNA-binding protein to modulate gene expression at
the post-transcriptional level (Fu et al., 1996; Miller et al., 2000).
We reasoned as a transcription factor, p53 may also regulate cer-
tain miRNA expression. In 2006, we ﬁrst systematically analyzed
the miRNA proﬁles in CRC cell lines HCT 116 with either wild-
type p53 or null-p53, and identiﬁed putative p53-binding sites in
nearly 40% of miRNA promoter regions (e.g., miR-34s, miR-192,
miR-215,miR-200c,miR-26; Xi et al., 2006b). miR-26a was exper-
imentally validated to be directly regulated by p53. Since then, this
has now become a new frontier in cancer research. Several recent
studies demonstrated a clear signiﬁcance of such regulatory rela-
tionship in various cancer types (Shin et al., 2009a,b; Zhou et al.,
2010).
Among p53-regulated miRNAs, miR-34a, miR-192, miR-215,
and miR-26a have been extensively studied in CRC. miR-34a was
shown to be directly regulated by p53 and suppress the prolifera-
tion of CRC cell lines HCT 116 and RKO in vitro and in vivo, and
its expression level was reduced in 36% of human CRC specimens.
The tumor suppressive function ofmiR-34awas a result of the sup-
pression of key cell cycle regulators such as the E2F transcription
factor pathway and activation of p53 and p21 (Chang et al., 2007;
He et al., 2007; Raver-Shapira et al., 2007; Tazawa et al., 2007).
Another important target of miR-34a is silent information regula-
tor 1 (SIRT1), and the apoptosis of CRCcells inducedby repression
of SIRT1 was dependent on p53 expression (Yamakuchi et al.,
2008). miR-26a has been demonstrated to impact colon cancer by
inﬂuencing apoptotic pathway by targeting BAK1 (Kulshreshtha
et al., 2007).
For other p53 mediated miRNAs such as miR-26a, miR-192,
and miR-215, the expression levels were reduced in CRC. miR-
192 and miR-215 can induce cell cycle arrest and enhance p53
mediated p21 expression when overexpressed in CRC cell lines (Xi
et al., 2006b; Braun et al., 2008; Georges et al., 2008; Song et al.,
2008; Karaayvaz et al., 2011). We further investigated the regulat-
ing mechanism of p53 level by miR-215 in CRC and discovered
a key target, denticleless protein homolog (DTL). The suppres-
sion of DTL by miR-215 triggered an up-regulation of p53 and
p21 (Song et al., 2010). DTL (RAMP, CDT2) is thought to play
an essential role in DNA synthesis, cell cycle progression, prolifer-
ation, and differentiation (Pan et al., 2006). It has been reported
that DTL controls cell cycle through many distinct mechanisms.
First, it is a component of the proliferating cell nuclear antigen
(PCNA) – coupled CUL4–DDB1 E3 ubiquitin ligase complex and
is required for degrading Cdt1 during S phase (Higa et al., 2006),
thereby preventing DNA replication (Sansam et al., 2006). Sec-
ondly, it has an important role in the early, radiation-induced
G2/M checkpoint, possibly through degrading key cell cycle regu-
lators in G2 phase by its ubiquitin ligase function (Sansam et al.,
2006). Moreover, PCNA-coupled CUL4/DDB1/DTL complex has
been reported to ubiquitinate and degrade key cell cycle pro-
teins such as p53, MDM2, p21, and E2F1, further emphasizing
the signiﬁcance of this ubiquitination system in cell cycle (Banks
et al., 2006; Nishitani et al., 2008; Shibutani et al., 2008). Although
miR-192 has almost identical sequences as miR-215, it does not
suppress DTL expression. miR-192 and miR-215 also localized at
different chromosomes. These results suggest that not only can
the functions of miRNAs be modulated by p53 status in CRC,
the tumor suppressive function of p53 can also be modulated by
the post-transcriptional controls of various miRNAs under differ-
ent stress and/or physiological conditions, providing p53 with a
greater ﬂexibility to control cell cycle and cell death. The impact of
miR-215 on several cellular processes [proliferation, cell cycle con-
trol, chemoresistance, epithelial–mesenchymal transition (EMT)]
was summarized in Figure 1.
miRNAs AND EPITHELIAL–MESENCHYMAL TRANSITION
Epithelial–mesenchymal transition is an evolutionarily conserved
developmental process (Thiery, 2003), and it has been proposed
as a key process for tumor invasion, metastasis, and carcino-
genesis (Yang and Weinberg, 2008). EMT is characterized by
a remarkable morphological change of epithelial cells from an
epithelial cobblestone phenotype to an elongated ﬁbroblastic
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FIGURE 1 | Impact of miR-215 on cell proliferation, cell cycle,
chemoresistance, and EMT. p53 and miR-215 form a positive feedback
regulatory mechanism to regulate cell cycle control. The expression of p53
was induced by the suppression of DTL, a critical component of the e
CUL4A–DDB1 E3 ubiquitin ligase complex, along with the p53 down
stream gene p21. The elevated p53 in turn up-regulates the expression of
miR-215. In addition, to DTL, miR-215 also suppresses the expression of
TS, DHFR, CDC7, MCM3, MCM10. miR-215 triggers cell cycle arrest at the
G2/M phase without triggering cell death, which contribute to
chemoresistance to TS and DHFR inhibitors in CSCs. miR-215 also
mediates EMT transition by targeting ZEB2 via TGFβ signaling pathway.
phenotype (mesenchymal phenotype) accompanied by increased
motility and invasive activity. During the acquisition of EMT
characteristics, cells lose epithelial cell–cell junctions, undergo
cytoskeleton reorganization, decrease the expression of proteins
that promote cell–cell contact such as E-cadherin and γ-catenin,
and increase the expression of mesenchymal markers such as
vimentin, ﬁbronectin, α-smooth muscle actin (SMA), and N-
cadherin. Moreover, an increased activity of matrix metallopro-
teinases (MMPs) like MMP-2, MMP-3, and MMP-9 is observed
during EMT, which can be associated with an invasive phenotype
(Wang et al., 2010c).
Recently, studies have shown that miRNAs regulate EMT
through the regulation of E-cadherin and its transcriptional
repressors such as zinc ﬁnger E-box-binding factors (ZEB;Gregory
et al., 2008b;Wang et al., 2010c). For example,miR-200 family and
miR-205 have been identiﬁed as key regulators of EMT by repress-
ing ZEB1 and ZEB2, which in turn repress the transcription of
several members in miR-200 family, suggesting a double-negative
feedback loop existed between these miRNAs and ZEBs to mod-
ulate the switch between epithelial and mesenchymal phenotype
in cancer cells (Bracken et al., 2008; Burk et al., 2008; Gregory
et al., 2008a, 2011). Moreover, it has been shown that TGF-β
treatment was directly associated with phenotypic and molecular
changes attributed to EMT, which led to the decreased expression
of miR-200 with the up-regulation of ZEBs, indicating that TGF-
β/ZEB/miR-200 signaling network can regulate the plasticity of
EMT (Gregory et al., 2011). Similar functions were also found in
miR-192/215,whichwas shown to regulate EMT indiabetic kidney
cells (Kato et al., 2007;Wang et al., 2010a). Another p53 mediated
miRNA,miR-194, also contributes directly to the EMT process by
suppressing the expression of BMI1 in endometrial cancer (Dong
et al., 2011).
Loboda et al. analyzed the gene expression proﬁle from 326
CRC specimens by microarrays, and identiﬁed around 5000 dif-
ferentially expressed genes, which were then divided into two
subpopulations based on ﬁrst principal component (PC1) analy-
sis. Several gene signatures were also found to be tightly associated
with PC1/EMT signature, such as TGF-β, RAS, proliferation, and
MYC. TGF-β and RAS have been shown as key regulators for EMT
process. They also proﬁled miRNAs in 70 CRC samples and found
that miR-200 family was the most signiﬁcant miRNA associated
with PC1/EMT signature. Moreover, miR-200 overexpression was
more abundant in tumors categorized as epithelial tumors, and
its down-regulation was more evident in mesenchymal tumor
category (Loboda et al., 2011).
In addition to the miR-200 family, other miRNAs were also
involved in EMT process during CRC development. TGF-β treat-
ment can trigger EMT transition in LIM1863, a three-dimensional
colon cancer organoid culture (Whitehead et al., 1987). Synergis-
tic treatment of TNF-α with TGF-β can signiﬁcantly accelerate
the process of morphological changes, however, TNF-α alone had
no effects (Bates and Mercurio, 2003). Cottonham et al. reported
that the expression levels of miR-21 andmiR-31 were signiﬁcantly
up-regulated during the EMT process in LIM 1863 induced by
TGF-β/TNF-α treatment. Ectopic expression of miR-21 and miR-
31 in LIM 1863 and other CRC cell lines increased their migratory
and invasive activity, and had positive effects on TGF-β induced
changes. Furthermore, the target of miR-21 and miR-31 mediat-
ing EMT was identiﬁed as T lymphoma invasion and metastasis
1 (TIAM1), a guanidine exchange factor for Rac GTPase. Over-
expression of Rac GTPase antagonized the EMT process induced
by TGF-β/TNF-α treatment and miR-21/miR-31 overexpression
(Cottonham et al., 2010). These results suggest that certain miR-
NAs might act at the downstream of TGF-β signaling pathway to
facilitate CRC invasion and metastasis.
Several other miRNAs such as miR-9 and miR-335 were
reported to enhance cancer metastasis by inhibition of E-cadherin
and SOX4 respectively (Tavazoie et al., 2008; Ma et al., 2010).
Down-regulation of miR-31 has been shown to promote breast
cancer cell migration, invasion, and metastasis, possibly through
up-regulation of its targets, such as integrin α5, radixin, and Rho
A (Valastyan et al., 2009, 2010). However, currently limited infor-
mation was available on the impact of miRNAs in EMT in CRC
development.
miRNAs AND COLON CANCER STEM-LIKE CELLS
Cancer stem-like cells (CSCs) are a small population of progeni-
tor cells, which are distinct from other cells within a tumor mass
based on morphology and function. The characteristics of CSCs
are self-renewal, asymmetric division, slow proliferation, and dif-
ferentiation into variable tumor cells (Clarke and Fuller, 2006).
CSC-enriched populations have been isolated fromCRCs based on
their surface markers (CD44, CD133, Lgr5, aldehyde dehydroge-
nase; Ricci-Vitiani et al., 2007; Boman andHuang,2008; Botchkina
et al., 2009; Huang et al., 2009; Fan et al., 2011). This small pop-
ulation of cells exhibited several unique characteristics, such as
formation of undifferentiated tumor spheres in serum-freemedia,
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differentiation intoCRCcells in response to serumand growth fac-
tors and increased resistance to chemotherapeutic drugs in vitro, as
well as rapid tumor formation in vivo,which contribute to the drug
resistance, cancer metastasis, and tumor recurrence (Ricci-Vitiani
et al., 2007). Due to the fundamental roles of miRNAs involved
in the developmental process, we reasoned that certain miRNAs
will contribute to the stem-like phenotype of CRC tumor cells and
chemoresistance.
Previous studies fromour laboratory have highlighted the asso-
ciation of miR-140 and miR-215 in colon CSCs (Song et al., 2009,
2010). Both of them can repress CRC cell proliferation and cause
cell cycle arrest. CD133high/CD44high population displayed typ-
ical CSC characteristics, low proliferation, and highly resistant to
chemotherapeutic drugs. After comparing miRNA levels between
CRC stem cells and control parental cells, we demonstrated that
miR-140 andmiR-215 expression levels were increased by fourfold
and threefold in CRC stem cells compared to control parental CRC
cells respectively (Song et al., 2009, 2010). Differentially expressed
miRNAswere also quantiﬁed inHT29 cells by isolating CRC stem-
like cells with CD133 marker, which displayed a higher efﬁciency
to form tumor spheres in vitro and tumors in nudemice. This pop-
ulation also showed elevated expression of stemness genes, such as
Wnt2, BMI1,OCT3/4, and Notch 1. After proﬁling the miRNAs in
CD133+ and CD133− population, 11 miRNAs were found to be
up-regulated inCSCpopulation, includingmiR-455-5p,miR-455-
3p, miR-105, miR-1826, miR-155, miR-494, miR-16-2*, miR-744,
miR-185, miR-423-5p, and miR-181b, and eight miRNAs were
down-regulated, including miR-429, miR-548d-5p, miR-31, miR-
151-5p, miR-151-3p, miR-221, miR-320, and miR-636 (Zhang
et al., 2011). Among these,miR-429, a member of miR-200 family,
and miR-155 has been reported to regulate CSC differentiation
and EMT (Kong et al., 2008; Park et al., 2008).
Empirical evidence connecting EMT with the CSC pheno-
type has been previous demonstrated (Mani et al., 2008). It was
reported that induction of EMT in immortalized human mam-
mary epithelial cells (HMLEs) resulted in the acquisition of mes-
enchymal traits and the expression of stem-cell markers. Epithelial
cells that have undergone EMT displayed stem-cell characteristics
such as the abilities to form mammospheres, soft agar colonies,
and tumors more efﬁciently. CSCs isolated from HMLE cultures
express markers similar to HMLE cells that have undergone EMT.
Thus, it has been suggested that EMT is able to generate cells
with properties of stem cells. Furthermore, Brabletz et al. (2005)
has reported that tumor cells at the tumor–host interface express
EMT-associated genes aswell as stemness-associated genes inCRC,
suggesting a relationship between EMT and CSCs. It has also been
demonstrated that many signaling pathways, such as Wnt, Notch,
and Hedgehog are directly involved in regulating EMT and CSC
self-renewal andmaintenance (Wang et al., 2010c). Recent reports
have described the involvement of several EMT-related miRNAs
in the regulation of CSCs. One of the most prominent examples is
miR-200c activated by p53, which suppresses the ability of normal
mammary epithelial cells to formmammary ducts and breast can-
cer stem cells to form tumors in vivo (Shimono et al., 2009; Chang
et al., 2011).
LIN28B, the repressor for let-7 biogenesis, was shown to
be overexpressed in several cancer types (Guo et al., 2006;
Viswanathan et al., 2009), and to induce pluripotency of somatic
ﬁbroblasts when co-expressed with OCT4, SOX2, and KLF4 (Yu
et al., 2007b). In CRCs, let-7 level was decreased accompanied by
increased level of LIN28B, which correlated with shorter patient
survival and higher probability of tumor recurrence. Ectopic
expression of LIN28B in immortalized intestinal epithelial cells
(IEC-6) enhanced cell migration and invasion. More importantly,
it switched normal epithelial cells to tumorigenic cells by soft agar
colony formation assay. LIN28B also increased the migration and
invasion of CRCcells,whichwas partially dependent on the inhibi-
tion of let-7 expression. Meanwhile, overexpression of LIN28B led
to the increased expression of intestinal stem-cell marker LGR5
and PROM1. CRC cells with constitutive expression of LIN28B
formed more tumors in vivo with higher metastasis as compared
with parental cells, suggesting the dual roles of LIN28B in CRC
development (King et al., 2011a,b).
miRNAs AND CRC DIAGNOSIS
The advantage of miRNAs as biomarkers is that they are highly
stable in archival formalin ﬁxed parafﬁn embedded (FFPE) tis-
sues and body ﬂuids (Xi et al., 2007; Chen et al., 2008; Mitchell
et al., 2008; Hui et al., 2009). The common approaches for dis-
covering miRNA based biomarkers is to quantify miRNAs from
either fresh frozen or archival FFPE tumor tissues, and to calculate
the miRNA ratio between normal and tumor tissue, and predict
the patients’ prognosis and responses to chemotherapy. In addi-
tion, several new methods have been developed to detect miRNAs
in plasma, serum and stool samples as non-invasive early screen-
ing approaches for CRC patients (Ng et al., 2009; Huang et al.,
2010; Link et al., 2010; Cheng et al., 2011). The list of miRNAs as
potential diagnostic, prognostic, and therapeutic candidates was
summarized in Table 1.
The ability to quantify miRNA expression from body ﬂuids
offers a potential huge advantage as a non-invasive approach for
cancer diagnosis. Ng et al. (2009) ﬁrst reported the quantiﬁca-
tion of miRNAs in the plasma from CRC patients by real-time
qRT-PCR. The results showed that miR-135b, miR-95, miR-222,
miR-17-3p, and miR-92 were increased in the plasma from CRC
patients when compared with control normal plasma. The ele-
vation of miR-17-3p and miR-92 was independently validated,
and this elevation signiﬁcantly decreased after surgical resection
of primary tumors. Moreover, the elevation of miR-92 was able
to distinguish CRCs from other diseases, including gastric cancer
and inﬂammatory bowel disease. Similar results were obtained for
miR-29a and miR-92a in CRC plasma (Huang et al., 2010), which
highlighted these miRNAs as potential novel biomarkers for CRC
early screening. However, before circulating miRNA based detec-
tion assay reaches to the clinical practice. A robust RNA extraction
technique and normalization of miRNA expression from body
ﬂuids remained to be key factors to ensure the accuracy of the
measurement.
Furthermore, the correlation between CRC stages and circu-
lating plasma miRNAs was also analyzed. Cheng et al. quanti-
ﬁed miR-21, miR-92, and miR-141 in two sets of CRC patients’
plasma cohorts by qRT-PCR, and found that only the miR-141
level was signiﬁcantly correlated with CRC stages, although all of
the three miRNAs showed differential expression in CRC plasma
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Table 1 | Biomarker and therapeutic candidates of miRNAs in
colorectal cancer.
miRNAs References
DIAGNOSTIC BIOMARKERS
miR-106a Link et al. (2010)
miR-141 Cheng et al. (2011)
miR-17-3p Ng et al. (2009)
miR-21 Link et al. (2010), Cheng et al. (2011)
miR-29a Huang et al. (2010)
miR-92 Ng et al. (2009), Huang et al. (2010), Cheng et al. (2011)
PROGNOSTIC BIOMARKERS
miR-106a Diaz et al. (2008)
miR-141 Cheng et al. (2011)
miR-143 Kulda et al. (2010)
miR-200c Xi et al. (2006a)
miR-21 Slaby et al. (2007), Schetter et al. (2008), Kulda et al.
(2010), Nielsen et al. (2011), Fassan et al. (2011)
miR-215 Karaayvaz et al. (2011)
Let-7 and LIN28B King et al. (2011a)
MODULATORS FOR CHEMOTHERAPY
miR-140 Song et al. (2009)
miR-143 Borralho et al. (2009)
miR-192 Song et al. (2008)
miR-215 Song et al. (2010)
miR-22 Li et al. (2011)
miR-31 Wang et al. (2010b)
miR-34a Akao et al. (2011)
miRNA REPLACEMENTTHERAPY
miR-143 Akao et al. (2010)
miR-145 Akao et al. (2010), Ibrahim et al. (2011)
when compared to normal controls. Overexpression of miR-141
was highly associated with stage IV CRC with poor prognosis.
It can distinguish stage IV CRC from other stages with 77.1%
sensitivity and 89.7% speciﬁcity. Further, when a plasma test of
miR-141 was combined with blood carcinoembryonic antigen
(CEA) test, a common biomarker used for CRC diagnosis, the
screening accuracy was further improved, providing a more accu-
rate screening program for CRC patients (Cheng et al., 2011). The
detailed mechanism of elevated miR-141 in plasma remained to
be determined.
In addition to plasma tests, a recent study used stool samples
from healthy person and CRC patients to analyze miRNA levels.
They showed that the RNA extraction from stools was feasible
and there were considerable amounts of miRNAs existing in the
samples. The miRNA levels remained constant in fecal samples
collected from the same person at different time. After comparing
the miRNA proﬁle from normal and CRC stool samples, miR-21
and miR-106a were found to be up-regulated in a CRC group
when compared to normal controls, and their expression level
decreased with advanced disease stages (Link et al., 2010). This
study suggested that fecal miRNA detection could be a feasible
method, and miR-21 and miR-106a are potential candidates for
biomarkers in CRC screening. However, reliable control miRNAs
have to be identiﬁed and fully validated. The stool samples are
rather complex and a standard sample preparation needs to be
established. Of note, none of these miRNA based biomarkers have
yet made to clinical practice. Larger cohorts of CRC stool sam-
ples are needed for independent validation, especially due to the
complex nature of the stool samples.
It has been observed that therewas a lack of correlation between
miRNAs that were up/down-regulated in tumor tissue with those
identiﬁed in the serum or plasma CRC patients. The lack of cor-
relation could be due to many reasons that need to be further
investigated. The alterations of circulatingmiRNA levelsmay be an
indicationof pathological changes and therefore,might bepossible
as biomarkers. However, it can also be just an indirect indicator as
one particularmiRNAexpression from tumor tissue can be indica-
tive of disease while its expression in circulation is not relevant.
The exact origin of miRNAs in circulation has not been thoroughly
deﬁned. One possibility is the release of miRNAs from lysed tumor
cells packed in microvesicles (e.g., exosomes) against degradation.
Recently it has been demonstrated thatmiRNAs can be transferred
between cells through microvesicles (Valadi et al., 2007; Hunter
et al., 2008). However, the exact mechanism of exosome forma-
tion and function of miRNAs in circulation still remained to be
determined (Kosaka et al., 2010). Additional studies focusing on
discovering tumor speciﬁc exosomesmay contribute to our further
understanding of the biological rules of circulating miRNAs.
miRNAs AND CRC PROGNOSIS
It is quite clear thatmiRNAs are involved in the tumorigenesis, dis-
ease progression, and ﬂuoropyrimidine-based chemosensitivity of
CRC. As a result, there is a great potential of miRNAs as prognos-
tic biomarkers for CRC. The ﬁrst report of miRNAs related to
colon cancer prognosis was reported by Xi et al. as they com-
pared expression levels of 10 miRNAs (let-7b, let-7g, miR-15b,
miR-181b, miR-191, miR-200c, miR-26a, miR-27a, miR-30a-5p,
and miR-30c) between 24 paired normal colon tissue and CRC
specimens, and correlated with patient survival. Four miRNAs
(miR-15b, miR-181b, miR-191, and miR-200c) were found to be
up-regulated in CRC tumors, andmiR-200c level was signiﬁcantly
correlated with CRC patient survival (Xi et al., 2006a). This study
provides the clinical signiﬁcance of miR-200c expression and CRC
patient survival. Subsequent studies clearly demonstrated that
miR-200c plays a key role in tumorigenesis and EMT transition
by targeting key mRNA targets.
In addition to miR-200c, the miRNAs from miR-17-92 clus-
ter (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, miR-92a-1,
and miR-106a) have been shown to be up-regulated in CRC tis-
sue when compared with normal colon mucosa except miR-18a
(Mendell, 2008; Diosdado et al., 2009). Moreover, the expression
level of its target, E2F1, was inversely related to that of miR-17-92
cluster (O’Donnell et al., 2005;Woods et al., 2007). The expression
level of miR-106a was associated with CRC stages, and its reduced
expression was correlated with shorter survival. However, over-
expression of miR-17-5p predicted shorter survival only at early
stages (Diaz et al., 2008).
It has been proposed that miR-21 acts as a potential onco-
gene. The expression of miR-21 was up-regulated in CRC tissue
with a signiﬁcant association with CRC prognosis (Slaby et al.,
2007; Schetter et al., 2008; Kulda et al., 2010; Fassan et al., 2011).
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Patients with higher miR-21 levels had shorter disease-free inter-
val (DFI) when compared with those with lower levels (Kulda
et al., 2010). Moreover, miR-21 was found be expressed mainly
in ﬁbroblast-like cells in the stroma of stage II CRC by in situ
hybridization, and the overexpression of miR-21 correlated with
shorter patient survival in stage II colon cancer but not in stage
II rectal cancer (Nielsen et al., 2011). Accordingly, the target of
miR-21, programmed cell death 4 (PDCD4), was inversely corre-
lated with miR-21 levels with a lower nuclear staining of PDCD4
in CRC specimens than that of normal controls (Fassan et al.,
2011). In contrast, miR-143, a potential tumor suppressor and
down-regulated in CRC, was found to be inversely correlated with
prognosis. Patients with higher level of miR-143 exhibited shorter
DFI (Kulda et al., 2010). These results suggest that due to the
impact of miRNA on many gene pathways and targets, the func-
tion of miRNA may be far more complex than simple deﬁnition
of oncogene or tumor suppressor gene.
The repressors of miRNAs were also shown to be associated
with CRC prognosis, such as LIN28B. King et al. (2011a) quan-
tiﬁed LIN28B expression levels in CRC samples by immunohis-
tochemistry, and discovered that stage I and II tumors had lower
LIN28B staining intensity, which then was signiﬁcantly correlated
with longer patient survival and less chance of cancer recurrence,
indicating the indirect role of miRNAs in the prediction of CRC
prognosis.
It is established that more than 80% of stage II and 65% of
stage III CRC patients can be cured by surgery alone without
adjuvant therapy (McLornan et al., 2010). Moreover, the 5-year
survival rates for stage II (78.5%) and stage III (54%) colon
cancer patients are much higher than stage IV patients (8.1%;
O’Connell et al., 2004). Therefore, it is crucial to investigate the
prognosis potential of miRNAs in stage II and III colon cancer
both to spare patients who can be cured by surgery alone from
unnecessary chemotherapy treatment, and to target a population
with long term survival with surgery and chemotherapy treat-
ment. Previously our laboratory has shown the critical functions
of miR-215 in CRC cell lines (Song et al., 2010). Recently, we fur-
ther demonstrated the clinical signiﬁcance of miR-215 mediated
DTL expression in 34 paired specimens of stage II and stage III
CRC patients prior to chemotherapy treatment. miR-215 levels
were signiﬁcantly decreased in colon cancer specimens compared
to adjacent normal tissues, and its expression was associated with
patient survival. Patients with low levels of miR-215 tended to
have longer survival than patients with high levels of miR-215.
Moreover, DTL, the target of miR-215, was found to be increas-
ingly expressed in CRC specimens both on mRNA and protein
levels, which was inversely correlated to miR-215 level, suggest-
ing both molecules as potential novel biomarkers for CRC patient
prognosis (Karaayvaz et al., 2011).
miRNAs AND CRC THERAPEUTICS
The major obstacle for the success of chemotherapy is due to the
anti-cancer drug resistance (Longley et al., 2006). Many studies
have shown that miRNAs can modulate the response of CRC cells
to chemotherapeutic drugs.
To understand the underlying mechanisms responsible for
drug resistance, we began to focus on the potential regulatory
impact of miRNAs on two important genes, dihydrofolate reduc-
tase (DHFR) and thymidylate synthase (TS). DHFR catalyzes the
reduction of dihydrofolate to tetrahydrofolate as the one-carbon
donor essential for the de novo synthesis of thymidylate (dTMP),
a precursor for DNA synthesis (Banerjee et al., 2002). Methotrex-
ate (MTX) is used as antifolate-based chemotherapy to inhibit
the activity of DHFR. TS catalyzes the reductive methylation of
dUMP to dTMP (Carreras and Santi, 1995). 5-ﬂuorouracil (5-
FU) as ﬂuoropyrimidine-based chemotherapy or tomudex (TDX)
as antifolate-based chemotherapy is used to inhibit the activity of
TS. Due to their critical functions, both DHFR and TS have been
the major anti-cancer targets for the past 50 years (Salonga et al.,
2000; Johnston et al., 2003; Wang et al., 2007). Recently, studies
from our laboratory have shed light on miRNAs and chemoresis-
tance mediated by DHFR and TS. miR-192 was shown to repress
CRC cell proliferation and cell cycle arrest, which was dependent
onwild-type p53 expression.Overexpression ofmiR-192 inhibited
DHFR protein level by translational arrest, and induced increased
chemosensitivity of CRC cells to MTX (Song et al., 2008). In the
case of miR-215, we demonstrated that the expression of both TS
and DHFR were suppressed by miR-215. However, despite this,
the overexpression of miR-215 also counter-intuitively decreased
chemosensitivity toMTX and TDX. This effect was due to reduced
cell proliferation and increased G2-cell cycle arrest mediated by
miR-215 by suppression of DTL,which rendered colon cancer cells
less sensitive to MTX and TDX treatment (Song et al., 2010). Sim-
ilar impact on chemoresistance was also found in miR-140, and
its overexpression in CRC cells led to increased chemoresistance
to MTX and 5-FU, which in part, was due to the reduced cell pro-
liferation by the inhibition of histone deacetylase 4 (HDAC4) and
the accumulation of CSC population. The knockdown of miR-140
expression in CRC stem cells restored their chemosensitivity to 5-
FU (Song et al., 2009), indicating thatmiRNAs and their inhibitors
can be potential candidates for adjuvant therapy in addition to
chemotherapy. In another report, the inhibition of miR-31 in CRC
cells was shown to decrease the chemoresistance to 5-FU (Wang
et al., 2010b).
On the other hand, miRNAs with tumor suppressor like func-
tions were also shown to modulate chemosensitivity in CRC. For
example, the overexpressionofmiR-143 inCRCcell lines increased
the chemosensitivity to 5-FU possibly through ERK5/NF-κB sig-
naling pathway (Borralho et al., 2009). miR-34a level was found
to be decreased in 5-FU-resistant DLD-1 CRC cells compared to
the parental cells, while its target, SIRT1, was found to be ele-
vated. The p53 and miR-34a positive feedback loop was silenced
in the 5-FU-resistant cells. The overexpression of miR-34a in the
resistant cells sensitized them to 5-FU treatment, which was medi-
ated by inhibition of SIRT1 and E2F3 signaling pathways (Akao
et al., 2011). This is quite different from the p53mediatedmiR-215
on chemosensitivity as overexpressed miR-215 caused cell cycle
arrest without triggering signiﬁcant cell death as miR-34 does.
Moreover, overexpression of miR-22 in p53-mutated CRC cells
led to repression of cell proliferation, induction of apoptosis and
increased chemosensitivity to paclitaxel. When miR-22 level was
increased, phosphatase and tensin homolog (PTEN) expression
was also elevated, and it resulted in the inhibition of Akt activa-
tion, reduction of metadherin (MTDH), and increased level of
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Bax and activated caspase-3, which contributed to higher apop-
totic activity and lower chemoresistance to paclitaxel (Li et al.,
2011).
In addition to the impact on chemosensitivity, miRNAs and
their inhibitors have been tested in several in vivo animal models
as a therapeutic agents based on their intrinsic tumor suppressive
and oncogenic functions. For example, let-7 miRNAs have been
shown to be reduced inmany cancer types, and proposed as tumor
suppressors since they inhibited multiple oncogenes (RAS, MYC,
HMGA2) and key regulators of cell cycle control genes (CDC25A,
CDK6, cyclin D2; Takamizawa et al., 2004; Johnson et al., 2005,
2007; Lee and Dutta, 2007; Mayr et al., 2007; Park et al., 2007;
Sampson et al., 2007; Yu et al., 2007a). Ectopic expression of let-
7 miRNAs in lung cancer cells and breast cancer cells has been
shown to prevent or reduce the tumor formation in mouse mod-
els (Johnson et al., 2007; Yu et al., 2007a; Esquela-Kerscher et al.,
2008; Kumar et al., 2008), and administration of synthetic let-
7 precursor to the established tumors in mice led to the tumor
regression (Trang et al., 2010). The latter study suggested miRNA
replacement as a novel therapeutic strategy for cancer patients.
However, the miRNA based anti-cancer therapy will likely face the
some of the same technical hurdles of siRNA based therapy.
miR-143 and miR-145 have been extensively studied in CRCs,
and as potential candidates for CRC treatment. BothmiRNAs have
been shown to be down-regulated in many cancer types (Akao
et al., 2006), especially in CRCs (Michael et al., 2003; Akao et al.,
2007; Slaby et al., 2007), and ectopic expression of miR-143 or
miR-145 suppressed tumor cell proliferation and triggered apop-
tosis of tumor cells in vitro and in vivo (Shi et al., 2007; Akao et al.,
2009, 2010; Sachdeva et al., 2009). Among the identiﬁed targets
for both miRNAs in CRCs, there are several important oncogenes
and transcription factors such as ERK5 and KRAS for miR-143
(Akao et al., 2006, 2009, 2010; Chen et al., 2009; Gao et al., 2011),
c-myc, insulin receptor substrate 1 (IRS1), YES, and STAT1 for
miR-145 (Shi et al., 2007; La Rocca et al., 2009; Sachdeva et al.,
2009; Gregersen et al., 2010). In mouse CRC xenograft models,
miR-145 was delivered systemically or locally to the tumors medi-
atedbypolyethylenimine (PEI),andbothmethods led todecreased
tumor burden, up-regulation of apoptosis and repression of miR-
145 targets, c-myc, and ERK5 (Ibrahim et al., 2011). To increase the
resistance to nucleases, chemically modiﬁed miR-143 was locally
delivered to human CRC xenografts via cationic liposomes. The
synthetic miR-143 had the addition of aromatic benzene-pyridine
like structure to its 3′-overhang region and sequence changes in
the passenger strand in miR-143 duplex, which showed higher
stability against nuclease digestion and greater anti-tumor activ-
ity when compared with endogenous miR-143 (Akao et al., 2010;
Kitade and Akao, 2010). These results suggest that synthetic miR-
NAsmay be potential candidates for the development of CRCRNA
replacement therapies. These results establish a foundation for the
pursuit of therapeutic potentials for both miR-143 and miR-145
in CRCs. With the continued advancement of in vivo delivery of
miRNA and its mimics, the therapeutic application of miRNAs for
cancer treatment is on the horizon.
CONCLUSION
Given the signiﬁcant role of miRNAs in many aspects of CRC
development such as proliferation, cell cycle control, invasion,
EMT, and maintained tumor stem-cell phenotype, we remain
hopeful that miRNA based therapeutics, diagnosis, and prognosis
may emerge in the near future to beneﬁt patients. Multi-center,
large patient cohort studies are clearly needed to fully validate
the clinical values of miRNA as biomarkers for CRCs. With the
progress in technology of miRNA detection and quantiﬁcation
such as RNA-Seq, personalized medicine based on miRNA bio-
markers will eventually emerge as new tools for the CRC disease
management due to the superior stability, broad impact on gene
pathways and targets.
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